|
Carotid Artery Thickness in HIV Infected and Uninfected Adults Clinical Trials Information presented on Clinical Trials Search is not designed to be a substitute for proven healthcare advice, travels to or treatment by using a genuine medical doctor. We are not physicians. Always confer with your doctor on Carotid Artery Thickness in HIV Infected and Uninfected Adults conditions. Clinical Trials Search.org is a site devoted to listing clinical research studies in human subjects. Carotid Artery Thickness in HIV Infected and Uninfected Adults Clinical research trials and Carotid Artery Thickness in HIV Infected and Uninfected Adults healthcare trials take place in many of cities across the United States of America. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials generally evaluate the effectiveness of new drugs. The function of the studies / undertakings is to answer specific human medical questions. Clinical trials are a popular means for mDs, government agencies, and private sector companies to find treatments for all forms of conditions, including Carotid Artery Thickness in HIV Infected and Uninfected Adults. Carotid Artery Thickness in HIV Infected and Uninfected Adults Clinical Trials and other clinical trials allow for volunteers to access medical treatment alternatives before they are available to the masses. Many times the test subjects undergo treatment for without cost, and occasionally they are compensated for their time. Occasionally there is a cost for a Carotid Artery Thickness in HIV Infected and Uninfected Adults clinical trial. Test subjects oftentimes recieve the best healthcare possible for their Carotid Artery Thickness in HIV Infected and Uninfected Adults condition. Hazards are a reality, nonetheless, and might include additional or frequent doctor trips, healthcare hazards (perhaps life-jeopardizing), and/or the treatment being ineffective. Trials are federally regulated with rigid guidelines to protect clinical trials subjects.
|
|
|
|
|
|
|
Home > "C" Clinical Trials Conditions > Carotid Artery Thickness in HIV Infected and Uninfected Adults  Carotid Artery Thickness in HIV Infected and Uninfected Adults
Carotid Artery Thickness in HIV Infected and Uninfected Adults
For Condition: Atherosclerosis,HIV Infections,HIV Seronegativity
Status: No longer recruiting
Sponsor(s): National Institute of Allergy and Infectious Diseases (NIAID) ,
Synopsis: The intima-media thickness (IMT) test is a low cost, non-invasive way to measure the thickness of the carotid artery (the large artery in the neck). The purpose of this study is to compare the thickness of the carotid artery among HIV infected adults taking protease inhibitors (PIs), HIV infected adults not taking PIs, and HIV uninfected adults, and to examine how the thickness may change over time.
Details: Determination of clinical, lipid, and non-lipid risk factors has been the traditional approach for gauging an individual's risk for coronary artery disease (CAD). However, the IMT test, which uses sound waves to measure the thickness of the carotid artery, has been found to diagnose CAD and predict a person's risk for heart disease as well as or better than lipid and non-lipid risk factors. This study will use the IMT test to see if anti-HIV treatment and HIV infection affect a patient's risk of developing atherosclerosis (hardening of the arteries) by comparing carotid artery thickness among HIV infected adults taking PIs, HIV infected adults not taking PIs, and HIV uninfected adults. There are 3 groups in this study. Group 1 will comprise HIV infected participants currently taking a PI-containing regimen. Group 2 will comprise HIV infected participants who are not taking PIs. Group 3 will comprise HIV uninfected participants. At each site, participants will be enrolled by "triads" consisting of an individual from each group. Each member of the triad will be closely matched by gender, age, smoking and menopausal status, race, and normal or hypertensive blood pressure. All 3 members of the triad must be identified before participants are registered to the study. All participants will visit the clinic at Weeks 1, 24, 48, 72, 96, and 144 (3 years). At each visit, participants will have a physical exam, medical history and waist/hip ratio assessment, blood collection, and an IMT test. The absolute value for carotid IMT will be compared among the 3 groups. Viral load and CD4 counts will also be measured in Group 1 and 2 participants.
Eligibility:
Study Type: Observational, Natural History, Longitudinal, Case Control, Prospective Study
Minimum Age/Maximum Age: 18 Years/
Genders: Both
Protocol Entry Criteria: Inclusion Criteria for Group 1 - HIV infected - Have taken at least 1 PI continuously for 2 or more years and are currently taking at least 1 PI. Stopping therapy for 4 weeks or less for management of side effects or to change therapy is allowed. - Viral load of 10,000 copies/ml or less Inclusion Criteria for Group 2 - HIV infected - Not currently receiving PIs or have not taken PIs in at least 3 months - Not planning to initiate PI therapy in the few months following study entry - Viral load of 10,000 copies/ml or less - If not currently on anti-HIV treatment, must have been on treatment for at least 6 months in the past Inclusion Criteria for Group 3 - HIV uninfected Exclusion Criteria for All Groups - Diabetes or current use of oral medications for diabetes - Kidney disease - ALT or AST greater than 2.5 times the upper limit of normal - Hypothyroidism - Family history (parents, brothers, sisters, or children) of heart attacks before age 55 in males and age 65 in females - Alcohol or drug abuse - Pregnant or plan to become pregnant during the study - Body mass index (BMI) greater than 30 - Systemic chemotherapy or radiation therapy - Systemic steroids (prednisone or equivalent) at doses greater than 5 mg/day for more than 30 consecutive days - History of coronary heart disease or stroke (including chest pain, heart attack, or abnormal stress test) - Uncontrolled hypertension
Total Enrollment: 132
Location and Contact Information:
Overall Study Official:
JudithCurrier, Study Chair, UCLA CARE Center
Univ of California, San Diego
San Diego, California, 92103
United States
Univ of Pennsylvania
Philadelphia, Pennsylvania, 19104
United States
UCLA CARE Ctr
Los Angeles, California, 90095
United States
Univ of Southern California / LA County USC Med Ctr
Los Angeles, California, 900331079
United States
Univ of Hawaii
Honolulu, Hawaii, 96816
United States
Harbor UCLA Med Ctr
Torrance, California, 90502
United States
Univ of Minnesota
Minneapolis, Minnesota, 55455
United States
Kaiser Foundation Hosp
Harbor City, California, 90710
United States
Kaiser Permanente LAMC
Los Angeles, California, 90027
United States
Univ of Washington
Seattle, Washington, 98104
United States
Additional Information:
Study ID Numbers: ACTG A5078; AACTG A5078
Study Start Date:
Record last reviewed: April 2004
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00007319
Other Atherosclerosis Studies:
1. A Phase I/II Double-Blind Controlled Trial to Determine the Safety and Immunogenicity of HIV-1 MN rgp160 Immuno AG Vaccine Therapy in HIV-Infected Individuals with Greater than or Equal to 500/mm3 CD4+ T Cells and 200-400/mm3 CD4+ T Cells
2. Safety and Effectiveness of 3 Anti-HIV Treatments in Patients Who Have Failed Previous Treatments Containing Nelfinavir
3. The Effect of Efavirenz and Nelfinavir on the Blood Levels of Certain Lipid-Lowering Drugs
4. Acetyl-L-Carnitine for the Treatment of NRTI-Associated Peripheral Neuropathy
5. A Study to Test the Effect of Cyclosporine on the Immune System of Patients with Early HIV Disease.
Related Studies:
Other Atherosclerosis Clinical Trials
Other California Clinical Trials
Other Los Angeles Clinical Trials
Carotid Artery Thickness in HIV Infected and Uninfected Adults
|
|
|
|
|
|
|
|
